Multistep screening and selection of COVID‐19 convalescent plasma donors at the early stage of the SARS‐CoV‐2 pandemic: A retrospective analysis

URN to cite this document:: urn:nbn:de:bvb:355-epub-528945
DOI to cite this document:: 10.5283/epub.52894

Brosig, Andreas Michael

; Ossner, Thomas ; Pamler, Irene ; Friedinger, Susanne ; Bica, Adelina‐Florina ; Mohrez, Morad ; Tlili, Ikram ; Mueller, Viktoria ; Becke, Christine ; Haehnel, Viola ; Baeuerlein, Veronika ; Stemmer, Barbara ; Burkhardt, Ralph

; Offner, Robert

License: Creative Commons Attribution Non-commercial No Derivatives 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 22 Sep 2022 05:28

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Abstract

Background and Aims
The COVID-19 pandemic reached Bavaria in February 2020. Almost simultaneously, Chinese physicians published reports on the first successful treatments with plasma from COVID-19 convalescent donors. With these silver linings on the horizon, we decided to establish the manufacturing of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody-containing plasma from COVID-19 convalescent donors at our site. Here we describe our donor selection process, built from the ground up, which enabled us to cope with the immense resonance after our social media call for donors.
Methods
As a first step, we created a specific questionnaire for telephone interviews applied by trained students to filter the wave of callers interested in plasma donation. Afterward, the medical staff evaluated the hotline questionnaires and chose eligible donors to be invited for on-site donor evaluation. Data documentation was performed with MS Excel, and statistical analyses were calculated with GraphPad Prism 8. A quantitative in-house ELISA was used to detect anti-SARS-CoV-2 antibodies and determine specific titers.
Results
Out of 1465 calls from potential plasma donors, we could register 420 persons with a completed questionnaire. Evaluation of questionnaires identified 222 of 420 persons as eligible for donation, and 55 were directly asked for on-site donor qualification. Subsequently, as anti-SARS-CoV-2 antibody titers ≥1:800 were required, we invited 89 of 222 potential donors for an antibody screening. This procedure resulted in another 28 potential donors for an on-site evaluation. Finally, 12 donors qualified with a titer of 1:400 and 24 with ≥1:800.
Conclusion
Identifying suitable COVID-19 convalescent plasma donors was expected to be highly time-consuming. Implementing a screening procedure with our hotline questionnaire helped us streamline the donor selection process and reduce the workload for the staff. We propose combining the described selection process with the later introduced on-site antibody screening as an effective strategy.

Owner only: item control page

Download Statistics

Altmetric

Alternative Statistics (altmetrics)

More literature (via CORE)

Details

Preview

Export bibliographical data

Abstract

Abstract

Download Statistics

Downloads

Alternative Statistics (altmetrics)

More literature (via CORE)

University Library